| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 27,354 | 23,520 | 22,524 | 21,060 |
| Cost of goods sold | 6,186 | 5,388 | 5,182 | 5,640 |
| Gross profit | 21,168 | 18,132 | 17,342 | 15,420 |
| Selling, general and administrative | - | - | 15,049 | 13,909 |
| Sales and marketing | 12,598 | 12,043 | - | - |
| Research and development | 6,576 | 6,845 | 7,440 | 5,754 |
| General and administrative | 4,594 | 6,068 | - | - |
| Total operating expenses | 23,768 | 24,956 | 22,489 | 19,663 |
| Loss from operations | -2,600 | -6,824 | -5,147 | -4,243 |
| Interest income | 667 | 718 | 793 | 754 |
| Interest expense | 1,645 | 2,059 | 2,153 | 2,182 |
| Other income (expense), net | 82 | -486 | -82 | 219 |
| Net loss and comprehensive loss | -3,496 | -8,651 | -6,589 | -5,452 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.11 | -0.26 | -0.21 | -0.19 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.11 | -0.26 | -0.21 | -0.19 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 33,134,606 | 32,863,031 | 31,480,911 | 29,444,625 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 33,134,606 | 32,863,031 | 31,480,911 | 29,444,625 |
NeuroPace Inc (NPCE)
NeuroPace Inc (NPCE)